# ASLAN Pharmaceuticals Limited (ASLN)

Source: https://www.quantisnow.com/company/ASLN
Generated: 2026-11-11T19:02:06.476Z

- Ticker: ASLN
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2018
- Website: aslanpharma.com

## About

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

## Latest ASLN news and filings

- 2024-09-06 11:41 UTC [SEC Form 25-NSE filed by ASLAN Pharmaceuticals Limited](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-aslan-pharmaceuticals-limited-5685291)
- 2024-08-08 15:36 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by ASLAN Pharmaceuticals Limited](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-aslan-pharmaceuticals-limited-5649830)
- 2024-07-18 11:55 UTC [Market Insight] [Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July](https://www.quantisnow.com/insight/top-3-health-care-stocks-which-could-rescue-your-portfolio-5614555)
- 2024-07-17 18:36 UTC [Market Insight] [Dow Jumps 200 Points; Synchrony Financial Posts Upbeat Earnings](https://www.quantisnow.com/insight/dow-jumps-200-points-synchrony-financial-posts-upbeat-earnings-5612953)
- 2024-07-17 17:28 UTC [Market Insight] [Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session](https://www.quantisnow.com/insight/why-aslan-pharmaceuticals-shares-are-trading-lower-by-over-38-5612856)
- 2024-07-17 16:10 UTC [Market Insight] [Why ASLAN Pharmaceuticals (ASLN) Shares Are Down 40%](https://www.quantisnow.com/insight/why-aslan-pharmaceuticals-asln-shares-are-down-40-5612712)
- 2024-07-17 16:03 UTC [Market Insight] [Crude Oil Rises 2%; Five Below Shares Plunge](https://www.quantisnow.com/insight/crude-oil-rises-2-five-below-shares-plunge-5612692)
- 2024-07-17 13:39 UTC [Market Insight] [Nasdaq Dips 300 Points; Johnson & Johnson Earnings Top Estimates](https://www.quantisnow.com/insight/nasdaq-dips-300-points-johnson-johnson-earnings-top-estimates-5612407)
- 2024-07-17 12:07 UTC [Market Chatter] [ASLAN Pharmaceuticals shares are trading lower after the company announced that its Singapore-incorporated, sole operating subsidiary has filed for voluntary liquidation.](https://www.quantisnow.com/insight/aslan-pharmaceuticals-shares-are-trading-lower-after-the-company-announced-5612069)
- 2024-07-17 11:29 UTC [SEC Form 6-K] [SEC Form 6-K filed by ASLAN Pharmaceuticals Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-aslan-pharmaceuticals-limited-5611883)
- 2024-07-17 11:28 UTC [Market Chatter] [ASLAN Pharmaceuticals Announced That Its Sole Operating Subsidiary Has Filed For Voluntary Liquidation And All Employees At ASLAN SG And Fellow Subsidiary ASLAN Pharmaceuticals Have Been Terminated Effective Immediately](https://www.quantisnow.com/insight/aslan-pharmaceuticals-announced-that-its-sole-operating-subsidiary-has-filed-5611866)
- 2024-07-17 11:25 UTC [ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation](https://www.quantisnow.com/insight/aslan-pharmaceuticals-announces-it-has-filed-for-voluntary-liquidation-of-5611862)
- 2024-07-15 18:32 UTC [Market Insight] [Crude Oil Moves Lower; Goldman Sachs Posts Upbeat Results](https://www.quantisnow.com/insight/crude-oil-moves-lower-goldman-sachs-posts-upbeat-results-5608289)
- 2024-07-15 17:23 UTC [Market Insight] [Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session](https://www.quantisnow.com/insight/why-solaredge-shares-are-trading-lower-by-12-here-are-5608218)
- 2024-07-15 16:05 UTC [Market Insight] [Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet](https://www.quantisnow.com/insight/nasdaq-surges-over-1-lexeo-therapeutics-shares-plummet-5608069)
- 2024-07-15 14:59 UTC [Market Chatter] [ASLAN Pharmaceuticals shares are trading lower after the company announced the receipt of a Nasdaq delisting determination.](https://www.quantisnow.com/insight/aslan-pharmaceuticals-shares-are-trading-lower-after-the-company-announced-5607938)
- 2024-07-15 13:47 UTC [Market Insight] [Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Falls In July](https://www.quantisnow.com/insight/dow-jumps-over-200-points-ny-empire-state-manufacturing-index-5607767)
- 2024-07-15 11:33 UTC [Market Chatter] [ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination For Non-Compliance Of Bid Price And Stockholders' Qquity Requirements](https://www.quantisnow.com/insight/aslan-pharmaceuticals-announces-receipt-of-nasdaq-delisting-determination-for-non-compliance-5607294)
- 2024-07-15 11:30 UTC [ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal](https://www.quantisnow.com/insight/aslan-pharmaceuticals-announces-receipt-of-nasdaq-delisting-determination-has-determined-5607280)
- 2024-07-15 11:29 UTC [SEC Form 6-K] [SEC Form 6-K filed by ASLAN Pharmaceuticals Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-aslan-pharmaceuticals-limited-5607279)
- 2024-07-03 12:55 UTC [Market Chatter] [Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times](https://www.quantisnow.com/insight/trading-halt-halt-status-updated-at-85500-am-et-quotation-5592291)
- 2024-07-02 23:50 UTC [Market Chatter] [Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending](https://www.quantisnow.com/insight/trading-halt-halted-at-75000-pm-et---trading-halt-5591708)
- 2024-06-24 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by ASLAN Pharmaceuticals Limited](https://www.quantisnow.com/insight/sec-form-effect-filed-by-aslan-pharmaceuticals-limited-5572086)
- 2024-06-21 12:08 UTC [Market Insight] [12 Health Care Stocks Moving In Friday's Pre-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-fridays-pre-market-session-5570079)
- 2024-06-20 12:22 UTC [Market Insight] [Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket](https://www.quantisnow.com/insight/why-vuzix-shares-are-trading-higher-by-around-15-here-5567316)
- 2024-06-19 20:30 UTC [Market Insight] [12 Health Care Stocks Moving In Wednesday's After-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-wednesdays-after-market-session-5566621)
- 2024-06-17 20:31 UTC [Market Insight] [12 Health Care Stocks Moving In Monday's After-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-mondays-after-market-session-5562362)
- 2024-06-14 21:00 UTC [Market Chatter] [ASLAN Pharmaceuticals Announces Plan To Implement ADS Ratio Change From 1 ADS Representing 25 Shares To 1 ADS Representing 200 Shares (1-For-8 ADS Split), Effective Date For The Ratio Change, July 3, 2024](https://www.quantisnow.com/insight/aslan-pharmaceuticals-announces-plan-to-implement-ads-ratio-change-from-5559766)
- 2024-06-14 20:54 UTC [ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change](https://www.quantisnow.com/insight/aslan-pharmaceuticals-announces-plan-to-implement-ads-ratio-change-5559727)
- 2024-06-14 20:46 UTC [SEC Form 6-K] [SEC Form 6-K filed by ASLAN Pharmaceuticals Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-aslan-pharmaceuticals-limited-5559676)
- 2024-06-14 20:30 UTC [SEC Form F-6 POS filed by ASLAN Pharmaceuticals Limited](https://www.quantisnow.com/insight/sec-form-f-6-pos-filed-by-aslan-pharmaceuticals-limited-5559459)
- 2024-06-12 20:32 UTC [SEC Form F-3 filed by ASLAN Pharmaceuticals Limited](https://www.quantisnow.com/insight/sec-form-f-3-filed-by-aslan-pharmaceuticals-limited-5554075)
- 2024-05-31 20:25 UTC [SEC Form 6-K] [SEC Form 6-K filed by ASLAN Pharmaceuticals Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-aslan-pharmaceuticals-limited-5529730)
- 2024-05-21 11:07 UTC [Market Chatter] [ASLAN Pharmaceuticals Announces Late-Breaking Poster Presentation Of Translational Data On Eblasakimab At American Thoracic Society International Conference](https://www.quantisnow.com/insight/aslan-pharmaceuticals-announces-late-breaking-poster-presentation-of-translational-data-on-5505780)
- 2024-05-21 11:00 UTC [ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference](https://www.quantisnow.com/insight/aslan-pharmaceuticals-presents-late-breaking-translational-data-on-eblasakimab-in-copd-5505736)
- 2024-05-09 11:51 UTC [Market Chatter] [ASLAN Pharma Q1 2024 GAAP EPADS $(1.29) Misses $(0.61) Estimate](https://www.quantisnow.com/insight/aslan-pharma-q1-2024-gaap-epads-129-misses-061-estimate-5475282)
- 2024-05-09 11:10 UTC [SEC Form 6-K] [SEC Form 6-K filed by ASLAN Pharmaceuticals Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-aslan-pharmaceuticals-limited-5474969)
- 2024-05-09 11:00 UTC [Public Offering] [ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update](https://www.quantisnow.com/insight/aslan-pharmaceuticals-reports-first-quarter-2024-financial-results-and-provides-5474826)
- 2024-05-07 11:41 UTC [SEC Form 6-K] [SEC Form 6-K filed by ASLAN Pharmaceuticals Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-aslan-pharmaceuticals-limited-5464850)
- 2024-05-07 11:30 UTC [ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event](https://www.quantisnow.com/insight/aslan-pharmaceuticals-to-present-additional-data-from-interim-analysis-of-5464748)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ASLN
- Earnings history: https://www.quantisnow.com/earnings/ASLN
- Dividend history: https://www.quantisnow.com/dividends/ASLN
- Insider transactions: https://www.quantisnow.com/insiders/ASLN
- Options chain: https://www.quantisnow.com/options/ASLN
- SEC 8-K filings only: https://www.quantisnow.com/company/ASLN/8-k
- RSS and alerts for ASLN: https://www.quantisnow.com/docs/rss-feeds.md